We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Nyrada is a biotechnology business based in Australia. Nyrada shares (NYR) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Nyrada has a trailing 12-month revenue of around $2.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.13 - $0.365 |
|---|---|
| 50-day moving average | $0.1657 |
| 200-day moving average | $0.211 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.026 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.15
| 1 week (2022-06-24) | 11.11% |
|---|---|
| 1 month (2022-06-02) | -3.23% |
| 3 months (2022-04-01) | -26.83% |
| 6 months (2021-12-31) | -37.50% |
| 1 year (2021-07-02) | -56.52% |
|---|---|
| 2 years (2020-07-02) | -14.29% |
| Revenue TTM | $2.3 million |
|---|---|
| Gross profit TTM | $160,972 |
| Return on assets TTM | -27.06% |
| Return on equity TTM | -46.75% |
| Profit margin | -159.53% |
| Book value | 0.078 |
| Market capitalisation | $23.4 million |
TTM: trailing 12 months
We're not expecting Nyrada to pay a dividend over the next 12 months.
Over the last 12 months, Nyrada's shares have ranged in value from as little as $0.13 up to $0.365. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Nyrada's is 1.4937. This would suggest that Nyrada's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; NYR-BI01, a neuroprotectant drug, to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney for advancement of preclinical neuroprotection compound for traumatic brain injury. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
